

In the name of God

Dear editor; salam from Iran and thank you very much for the kind consideration of my article. I prepared the manuscript as your instructions. Actually reviewers did not ask for revisions and it was accepted as its original version. The English revision was made extensively, however I am unable to provide further English revisions by international proof-reading institutions. I believe the current version of the article is totally improved, but if you think it needs further revisions and you know people who can provide this task, I would agree if they should be included into the author list or as in acknowledgement, according to your journal instructions.

The following comes a clean copy of the manuscript followed by a highlighted version that shows the parts that had been revised.

Sincerely yours
Saeed Taheri M.D.
Iran

Heterogeneity in Cardiorenal Protection by SGLT2 Inhibitors in Heart Failure across the Ejection Fraction

Strata: Systematic Review & Meta-Analysis

By Saeed Taheri M.D.

New Lahijan Scientific Foundation; Lahijan; Iran

Email: taherimd@gmail.com

Reviewer #1:

Scientific Quality: Grade B (Very good)

Language Quality: Grade B (Minor language polishing)

Conclusion: Accept (General priority)

Specific Comments to Authors: This manuscript aims to find out the differential effects of SGLT2i on the cardiorenal outcome of heart failure patients across ejection fraction levels, and the result suggested that heart failure patients with lower ejection fraction and lower NYHA sub-classifications were found more likely to benefit from gliflozin therapy. Further research are needed to find the patient subgroups with the highest benefits or adverse events in response to SGLT2i. The method is appropriate, the conclusion is reliable, the discussion is sufficient, and it is recommended to accept.

4 LANGUAGE POLISHING REQUIREMENTS FOR REVISED MANUSCRIPTS SUBMITTED BY AUTHORS WHO ARE NON-NATIVE SPEAKERS OF ENGLISH

As the revision process results in changes to the content of the manuscript, language problems may exist in the revised manuscript. Thus, it is necessary to perform further language polishing that will ensure all grammatical, syntactical, formatting and other related errors be resolved, so that the revised manuscript will meet the publication requirement (Grade A).

Authors are requested to send their revised manuscript to a professional English language editing company or a native English-speaking expert to polish the manuscript further. When the authors submit the subsequent polished manuscript to us, they must provide a new language certificate along with the manuscript.

Once this step is completed, the manuscript will be quickly accepted and published online. Please visit the following website for the professional English language editing companies we recommend:

<https://www.wjnet.com/bpg/gerinfo/240>.

5 ABBREVIATIONS

In general, do not use non-standard abbreviations, unless they appear at least two times in the text preceding the first usage/ definition. Certain commonly used abbreviations, such as DNA, RNA, HIV, LD50, PCR, HBV, ECG, WBC, RBC, CT, ESR, CSF, IgG, ELISA, PBS, ATP, EDTA, and mAb, do not need to be defined and can be used directly.

The basic rules on abbreviations are provided here:

- (1) Title:** Abbreviations are not permitted. Please spell out any abbreviation in the title.
- (2) Running title:** Abbreviations are permitted. Also, please shorten the running title to no more than 6 words.
- (3) Abstract:** Abbreviations must be defined upon first appearance in the Abstract. Example 1: Hepatocellular carcinoma (HCC). Example 2: *Helicobacter pylori* (*H. pylori*).
- (4) Key Words:** Abbreviations must be defined upon first appearance in the Key Words.
- (5) Core Tip:** Abbreviations must be defined upon first appearance in the Core Tip. Example 1: Hepatocellular carcinoma (HCC). Example 2: *Helicobacter pylori* (*H. pylori*)
- (6) Main Text:** Abbreviations must be defined upon first appearance in the Main Text. Example 1: Hepatocellular carcinoma (HCC). Example 2: *Helicobacter pylori* (*H. pylori*)
- (7) Article Highlights:** Abbreviations must be defined upon first appearance in the Article Highlights. Example 1: Hepatocellular carcinoma (HCC).

Example 2: *Helicobacter pylori* (*H. pylori*)

- (8) Figures:** Abbreviations are not allowed in the Figure title. For the Figure Legend text, abbreviations are allowed but must be defined upon first appearance in the text. Example 1: A: Hepatocellular carcinoma (HCC) biopsy sample; B: HCC-adjacent tissue sample. For any abbreviation that appears in the Figure itself but is not included in the Figure Legend textual description, it will be defined (separated by semicolons) at the end of the figure legend. Example 2: BMI: Body mass index; US: Ultrasound.

(9) Tables: Abbreviations are not allowed in the Table title. For the Table itself, please verify all abbreviations used in tables are defined (separated by semicolons) directly underneath the table. Example 1: BMI: Body mass index; US: Ultrasound.

6 EDITORIAL OFFICE'S COMMENTS

Authors must revise the manuscript according to the Editorial Office's comments and suggestions, which are listed below:

(1) Science editor:

The manuscript has been peer-reviewed, and it's ready for the first decision.

(2) Company editor-in-chief:

I have reviewed the Peer-Review Report, the full text of the manuscript, and the relevant ethics documents, all of which have met the basic publishing requirements of the World Journal of Nephrology, and the manuscript is conditionally accepted. I have sent the manuscript to the author(s) for its revision according to the Peer-Review Report, Editorial Office's comments and the Criteria for Manuscript Revision by Authors. However, the quality of the English language of the manuscript does not meet the requirements of the journal. Before final acceptance, the author(s) must provide the English Language Certificate issued by a professional English language editing company. Please visit the following website for the professional English language editing companies we recommend: <https://www.wjgnet.com/bpg/gerinfo/240>. Before final acceptance, uniform presentation should be used for figures showing the same or similar contents; for example, "Figure 1 Pathological changes of atrophic gastritis after treatment. A: ...; B: ...; C: ...; D: ...; E: ...; F: ...; G: ...". Please provide the original figure documents. Please prepare and arrange the figures using PowerPoint to ensure that all graphs or arrows or text portions can be reprocessed by the editor. In order to respect and protect the author's intellectual property rights and prevent others from misappropriating figures without the author's authorization or abusing figures without indicating the source, we will indicate the author's copyright for figures originally generated by the author, and if the author has used a figure published elsewhere or that is copyrighted, the author needs to be authorized by the previous publisher or the copyright holder and/or indicate the reference source and copyrights. Please check and confirm whether the figures are original (i.e. generated de novo by the author(s) for this paper). If the picture is 'original', the author needs to add the following copyright information to the bottom right-hand side of the picture in PowerPoint (PPT): Copyright ©The Author(s) 2023. Authors are required to provide standard three-line tables, that is, only the top line, bottom line, and column line are displayed, while other table lines are hidden. The contents of each cell in the table should conform to the editing specifications, and the lines of each row or column of the table should be aligned. Do not use carriage returns or spaces to replace lines or vertical lines and do not segment cell content. Before final acceptance, when revising the manuscript, the author must supplement and improve the highlights of the latest cutting-edge research results, thereby further improving the content of the manuscript. To this end, authors are advised to apply a new tool, the RCA. RCA is an artificial intelligence technology-based open multidisciplinary citation analysis

database. In it, upon obtaining search results from the keywords entered by the author, "Impact Index Per Article" under "Ranked by" should be selected to find the latest highlight articles, which can then be used to further improve an article under preparation/peer-review/revision. Please visit our RCA database for more information at: <https://www.referencecitationanalysis.com/>.

7 STEPS FOR SUBMITTING THE REVISED MANUSCRIPT

Step 1: Author Information

Please click and download the [Format for authorship, institution, and corresponding author guidelines](#), and further check if the authors names and institutions meet the requirements of the journal.

Step 2: Manuscript Information

Please check if the manuscript information is correct.

Step 3: Abstract, Main Text, and Acknowledgements

(1) Guidelines for revising the content: Please download the guidelines for Original articles, Review articles, or Case Report articles for your specific manuscript type (Systematic Reviews) at: <https://www.wignet.com/bpg/GerInfo/291>. Please further revise the content your manuscript according to the Guidelines and Requirements for Manuscript Revision.

(2) Format for Manuscript Revision: Please update the format of your manuscript according to the Guidelines and Requirements for Manuscript Revision and the Format for Manuscript Revision. Please visit <https://www.wignet.com/bpg/GerInfo/291> for the article type-specific guidelines and formatting examples.

(3) Requirements for Article Highlights: If your manuscript is an Original Study (Basic Study or Clinical Study), Meta-Analysis, or Systemic Review, the "Article Highlights" section is required. Detailed writing requirements for the "Article Highlights" can be found in the Guidelines and Requirements for Manuscript Revision.

(4) Common issues in revised manuscript. Please click and download the [List of common issues in revised manuscripts by authors and comments](#) (PDF), and revise the manuscript accordingly.

Step 4: References

Please revise the references according to the [Format for References Guidelines](#), and be sure to edit the reference using the reference auto-analyser.

Step 5: Footnotes and Figure Legends

(1) Requirements for Figures: Please provide decomposable Figures (in which all components are movable and editable), organize them into a single PowerPoint file, and submit as "85930-Figures.pptx" on the system. The figures should be uploaded to the file destination of "Image File". Please check and confirm whether the figures are original (i.e. generated de novo by the author(s) for this paper). If the picture is 'original', the author needs to add the following copyright information to the bottom right-hand side of the picture in PowerPoint (PPT): Copyright ©The Author(s) 2022. Please click to download the sample document: [Download](#).

(2) Requirements for Tables: Please provide decomposable Tables (in which all components are movable and editable), organize them into a single Word file, and submit as "85930-Tables.docx" on the system. The tables should be uploaded to the file destination of "Table File".

Reminder: Please click and download the [Guidelines for preparation of bitmaps, vector graphics, and tables in revised manuscripts](#) (PDF), and prepare the figures and tables of your manuscript accordingly.

Step 6: Automatically Generate Full-Text Files

Authors cannot replace and upload the "Manuscript File" separately. Since we only accept a manuscript file that is automatically generated, please download the "Full Text File" or click "Preview" to ensure all the contents of the manuscript automatically generated by the system are correct and meet the requirements of the journal. If you find that there is content that needs to be modified in the Full-Text File, please return to the corresponding step(s), modify and update the content, and save. At this point, you then have to click the "Save & Continue" button in Step 5 and the F6Publishing system will automatically regenerate the Full-Text File, and it will be automatically stored.

Step 7: Upload the Revision Files

For all required accompanying documents (listed below), you can begin the uploading process *via* the F6Publishing system. Then, please download all the uploaded documents to ensure all of them are correct.

- (1) 85930-Answering Reviewers
- (2) 85930-Audio Core Tip
- (3) 85930-Biostatistics Review Certificate
- (4) 85930-Conflict-of-Interest Disclosure Form
- (5) 85930-Copyright License Agreement
- (6) 85930-Approved Grant Application Form(s) or Funding Agency Copy of any Approval Document(s)
- (7) 85930-Non-Native Speakers of English Editing Certificate
- (8) 85930-Video
- (9) 85930-Image File
- (10) 85930-Table File
- (11) 85930-PRISMA 2009 Checklist
- (12) 85930-Supplementary Material

If your manuscript has supportive foundations, the approved grant application form(s) or funding agency copy of any approval document(s) must be provided. Otherwise, we will delete the supportive foundations.

If your manuscript has no “Video” or “Supplementary Material”, you do not need to submit those two types of documents.

8 COPYRIGHT LICENSE AGREEMENT

All authors should accept and sign the Copyright License Agreement (CLA), following the link sent in individual emails to each author. After all authors have accepted and signed their respective CLA, the Corresponding Author is responsible for downloading the signed CLA by clicking on the “Download” button in the CLA page, re-storing it as “PDF”, and then uploading it to the file destination of “Copyright License Agreement”. If any of the authors do not accept to sign the CLA, the manuscript will not be accepted for publication.

Reminder: If any of the authors do not receive the email of CLA, please check the spam folder. If the author still can't find the email, please contact us via email at: submission@wjgnet.com.

9 CONFLICT-OF-INTEREST DISCLOSURE FORM

Please click and download the fillable [ICMJE Form for Disclosure of Potential Conflicts of Interest](#) (PDF), and fill it in. The Corresponding Author is responsible for filling out this form. Once filled out completely, the Conflict-of-Interest Disclosure Form should be uploaded to the file destination of ‘Conflict-of-Interest Disclosure Form’.

Best regards,

Jin-Lei Wang, Company Editor-in-Chief, Editorial Office

Baishideng Publishing Group Inc

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Telephone: +1-925-399-1568

E-mail: j.l.wang@wjgnet.com

Help desk: <https://www.f6publishing.com/helpdesk>

Online Submission: <https://www.f6publishing.com/>

<https://www.wjgnet.com>

About Baishideng

Baishideng Publishing Group (*Baishideng*), founded on January 15, 1993, is a biomedical publishing company accredited by the Committee on Publication Ethics, editing and publishing more than 47 academic journals in Chinese and English. All of the *Baishideng*'s academic journals are published using an open access and single-blind external peer-review model, with some high-quality academic journals being included in the Science Citation Index Expanded, Emerging Sources Citation Index, MEDLINE, PubMed, PubMed Central, Scopus, *Reference Citation Analysis* (RCA), and other important databases. *Baishideng* relies on its industry leading *F6Publishing* system, which features functionalities covering the entire publication process, from manuscript submission to online publishing, including an article quality tracking system, author evaluation system, and reader evaluation system. In addition, *Baishideng* has the world's only RCA system, an open and transparent high-quality academic article evaluation service platform for various categories that is freely available to authors and readers. The functions of RCA include Find an Article, Find a Category, Find a Journal, Find a Scholar, and Find an Academic Assistant.